<DOC>
	<DOCNO>NCT02187029</DOCNO>
	<brief_summary>The purpose study assess effect PF-06743649 lowering serum uric acid subject suffer gout follow 14 day dosing , well assess safety tolerability .</brief_summary>
	<brief_title>Efficacy , Safety And Tolerability Of PF-06743649 In Gout Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<criteria>Subject meet diagnosis gout per American Rheumatism Association Criteria Classification acute Arthritis Primary Gout . Subjects take urate lower therapy time screen must willing discontinue prior urate lower therapy time Screening Visit 1 completion study period Day 16 . Subjects take urate lower therapy time screen must serum urate level &gt; = 8.0 mg/dL time second screening visit . Subjects NOT take urate lower therapy time screen must serum urate level &gt; = 8.0 mg/dL screen visit 1 2 . Positive medical history current evidence medical psychiatric condition/disease , ECG laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment Investigator , would make subject inappropriate entry study . Chronic kidney disease classify moderate severe ( Clinical Practice Guideline , National Kidney Foundation ) 12 ; GFR &lt; 60 mL/min/1.73m2 calculate CockcroftGault equation . Subjects current tophaceous gout . Gout flare resolve least 2 week prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Hyperuricemia</keyword>
	<keyword>gout</keyword>
	<keyword>serum uric acid</keyword>
</DOC>